These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 24575935)
1. Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer. Ciruelos E; Jackisch C Expert Rev Anticancer Ther; 2014 May; 14(5):511-21. PubMed ID: 24575935 [TBL] [Abstract][Full Text] [Related]
2. [Clinical experience of nab-Paclitaxel treatment in 31 patients with breast cancer]. Tauchi Y; Kashiwagi S; Ishihara S; Asano Y; Sakimura C; Kurata K; Tokumoto M; Morisaki T; Noda S; Kawajiri H; Takashima T; Onoda N; Hirakawa K Gan To Kagaku Ryoho; 2014 Nov; 41(12):1948-50. PubMed ID: 25731385 [TBL] [Abstract][Full Text] [Related]
3. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Henderson IC; Bhatia V Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452 [TBL] [Abstract][Full Text] [Related]
4. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Montero AJ; Adams B; Diaz-Montero CM; Glück S Expert Rev Clin Pharmacol; 2011 May; 4(3):329-34. PubMed ID: 22114779 [TBL] [Abstract][Full Text] [Related]
5. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Dranitsaris G; Coleman R; Gradishar W Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958 [TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain. Alba E; Ciruelos E; López R; López-Vega JM; Lluch A; Martín M; Muñoz M; Sánchez-Rovira P; Seguí MÁ; Liria MR; Pérez-Alcántara F Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):381-91. PubMed ID: 23534988 [TBL] [Abstract][Full Text] [Related]
7. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. O'Shaughnessy J; Gradishar WJ; Bhar P; Iglesias J Breast Cancer Res Treat; 2013 Apr; 138(3):829-37. PubMed ID: 23563958 [TBL] [Abstract][Full Text] [Related]
8. Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases. Xie Y; Gong C; Zhang J; Wang L; Cao J; Tao Z; Li T; Zhao Y; Li Y; Hu S; Wang B; Hu X BMC Cancer; 2021 Nov; 21(1):1174. PubMed ID: 34727875 [TBL] [Abstract][Full Text] [Related]
9. Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis. Aapro M; Tjulandin S; Bhar P; Gradishar W Breast; 2011 Oct; 20(5):468-74. PubMed ID: 21843943 [TBL] [Abstract][Full Text] [Related]
10. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P; McGuire JR; Iglesias J Clin Breast Cancer; 2012 Oct; 12(5):313-21. PubMed ID: 22728026 [TBL] [Abstract][Full Text] [Related]
11. A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer. Yamamoto S; Maeda N; Nagashima Y; Kubo H; Sato Y; Matsui H; Inoue Y; Shindo Y; Kanekiyo S; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yoshino S; Hazama S; Oka M; Nagano H Breast Cancer; 2017 Nov; 24(6):783-789. PubMed ID: 28439763 [TBL] [Abstract][Full Text] [Related]
12. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. Megerdichian C; Olimpiadi Y; Hurvitz SA Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997 [TBL] [Abstract][Full Text] [Related]
13. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer. Dranitsaris G; Cottrell W; Spirovski B; Hopkins S J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903 [TBL] [Abstract][Full Text] [Related]
15. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors. Lluch A; Alvarez I; Muñoz M; Seguí MÁ; Tusquets I; García-Estévez L Crit Rev Oncol Hematol; 2014 Jan; 89(1):62-72. PubMed ID: 24071503 [TBL] [Abstract][Full Text] [Related]
16. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer. Vishnu P; Roy V Womens Health (Lond); 2010 Jul; 6(4):495-506. PubMed ID: 20597612 [TBL] [Abstract][Full Text] [Related]
17. [Efficacy of supportive care for albumin-bound paclitaxel(nab-paclitaxel)in 20 patients with metastatic breast cancer]. Yamada C; Yonezawa M; Shimizu Y; Taga R; Kashihara H; Tsuji K; Murata T; Yoshino H Gan To Kagaku Ryoho; 2014 Jan; 41(1):77-81. PubMed ID: 24423956 [TBL] [Abstract][Full Text] [Related]
19. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941 [TBL] [Abstract][Full Text] [Related]
20. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Petrelli F; Borgonovo K; Barni S Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]